Research Summary
Thymosin Alpha-1 is a naturally occurring thymic peptide studied extensively for its role in immune system regulation, host defense signaling, and immune cell maturation.
Evidence profile
Controlled human evidence
10 cited publications · 1 primary trial
Findings below belong to the studies that reported them. They describe the material and conditions those authors used, not this product, and not an outcome to expect.
Naz RK et al. · Archives of andrology · 1995
The study reportedIt would appear that T alpha 1 may have clinical application in the diagnosis and treatment of male infertility especially mediated through defective sperm function.
Tian Y et al. · Frontiers in immunology · 2025
The study reportedTα1 can regulate the balance of immune cells and alleviate immune suppression in SAP patients, including increasing CD4+ T cells and CD4+/CD8+ ratios. Tα1 may exert anti-inflammatory and extrapancreatic infection-preventive effects on SAP patients and improve their condition or prognosis.
Cao A et al. · Journal of the College of Physicians and Surgeons--Pakistan : JCPSP · 2024
The study reportedMore high-quality randomised controlled trials are needed to further confirm Thymosin alpha 1 efficacy. Key Words: Thymosin alpha 1, Efficacy, Acute exacerbation of chronic obstructive pulmonary disease, Meta-analysis.
Dinetz E et al. · Alternative therapies in health and medicine · 2024
The study reportedBased on substantial evidence from clinical trials, Tα1 emerges as a well-tolerated and effective immune modulator. The FDA›s restriction appears unfounded, as Tα1 has shown safety and efficacy beyond the initially specified conditions.
Soeroto AY et al. · Inflammopharmacology · 2023
The study reportedOur study suggests that treatment with thymosin alpha-1 may reduce mortality rate in moderate to critical COVID-19 patients. Randomized clinical trials (RCTs) are still required to verify the findings of our study.
Shehadeh F et al. · The Journal of infectious diseases · 2023 · PMID 36056913
Minutolo A et al. · International immunopharmacology · 2023 · PMID 36989892
Wang T et al. · Zhonghua wei zhong bing ji jiu yi xue · 2022 · PMID 35728851
Liu J et al. · Frontiers in immunology · 2021 · PMID 34408744
Liu K et al. · Cell reports. Medicine · 2024 · PMID 39357524
Published studies summarised here concern the specific investigational or pharmaceutical materials and study conditions described by their authors. Their findings are not performance claims for Lucid Peptides material. Citations verified against PubMed on 2026-08-09.
Thymosin Alpha-1 is approved in some regions for specific indications and is presented here solely in the context of published scientific research.